Business Wire: Sound Pharma Announces Positive Phase 3 Results for the Treatment of Meniere’s Disease with SPI-1005 Sound Pharma Announces Positive Phase 3 Results for the Treatment of Meniere’s Disease with SPI-1005 Topline results were announced from a phase 3 trial evaluating SPI-1005 (ebselen) for the treatment of Meniere disease, an inner ear disorder that results in vertigo, hearing loss, and tinnitus. The ... Business Wire: Sound Pharma Announces Phase 3 Study Completion of SPI-1005 for the Treatment of Meniere’s Disease SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals is pleased to announce that the Phase 3 clinical trial involving SPI-1005, a novel anti-inflammatory, for the treatment of Meniere’s Disease (STOPMD-3) ...
Sound Pharma Announces Phase 3 Study Completion of SPI-1005 for the Treatment of Meniere’s Disease Nystagmus during vertigo attacks in patients with Meniere disease can be video-recorded with a mobile phone and provide a helpful therapeutic aid, according to a study published online Dec. 12 in the ... MSN: GERD May Be Linked to Ear Disorders, Including Tinnitus, Meniere Disease MONDAY, Sept. 8, 2025 (HealthDay News) -- Gastroesophageal reflux disease (GERD) may be associated with an increased risk for tinnitus, Meniere disease, vestibular dysfunction, and sensorineural ...
meniere's disease treatment, The Times of India on MSN: What are the real causes and treatments for Ménière's Disease? Monthly Prescribing Reference: Oral Glutathione Peroxidase Mimetic Looks Promising for Meniere Disease Deep learning techniques can enhance diagnosis of Meniere disease (MD) and severity grading, according to a study published in the January issue of Medical Physics. For patients with Meniere disease ... Business Wire: Sound Pharmaceuticals Receives FDA Breakthrough Therapy Designation for SPI-1005 to Treat Meniere’s Disease Sound Pharmaceuticals Receives FDA Breakthrough Therapy Designation for SPI-1005 to Treat Meniere’s Disease
